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Chemotherapy of non-small cell lung carcinoma guided by an in vitro drug
resistance assay measuring total tumour cell kill
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'Pettis Memorial Veterans Hospital, Loma Linda; 2Loma Linda University School ofMedicine; 'Veterans Affairs Medicine
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Summary Specimens from 45 patients with previously-untreated non-small cell lung cancer (NSCLC) were
tested for in vitro chemosensitivity to ten drugs utilising the DiSC assay, which measures cell kill in the total
(largely non-dividing) tumour cell population. Thirty-five assays were successful and 25 patients with advanced
disease subsequently received chemotherapy with the 'best' three drugs selected by the assay. Six patients were
Karnofsky performance status 60 or less and the median pretreatment weight loss was 8.5%. Nine patients
had a partial response (response rate = 36%; 95% confidence interval = 17-55%) and the median survival of
all patients was 202 days. Specimens from responding patients were significantly more sensitive in the assay to
drugs in general (especially to etoposide and to 'natural product' drugs) and to the drugs used in treatment
than were specimens from non-responding patients. In vitro drug resistance differences between responding and
non-responding patients were of greater significance than were differences between other clinical and labora-
tory measurements. Assay results classified patients into two cohorts, having relatively high and low prob-
abilities of responding to chemotherapy. Assay results also identified patient cohorts with above average and
below average durations of survival. Five patients (20%) were found to have tumours with extreme drug
resistance (EDR), defined as assay results for the average of all ten tested drugs falling greater than one
standard deviation more resistant than the median for all tumours assayed, and none of these patients with
EDR responded to chemotherapy.
No single program of chemotherapy has emerged as the
standard of treatment for patients with advanced non-small
cell lung cancer (NSCLC). Randomised comparisons have
covered a ranged of options including multidrug and single
drug therapy and no chemotherapy (Mulshine et al., 1986;
Hansen, 1987). Therapeutic choice has often been without
significant impact on survival. Where statistically significant
survival improvement has been reported the magnitude of the
benefit has been modest and caution seems appropriate in
weighing this benefit vs the toxicity from the treatment.
One hope for improving treatment outcome has been the
provision of customised treatment on the basis of individual
tumour properties. From December 1983 through August
1986 we investigated this approach with a pilot study of
individualised chemotherapy for NSCLC selected on the
basis of an in vitro drug resistance assay. The assay chosen
was a dye exclusion assay (the DiSc Assay) which has receiv-
ed extensive study in haematologic neoplasms (Weisenthal et
al., 1984; Weisenthal et al., 1986; Bird et al., 1985; Bosanquet
et al., 1983; Bird et al., 1986; Tidefelt et al., 1989; Kirkpat-
rick et al., 1990; Lathan et al., 1990; Bosanquet, 1991), but
more preliminary evaluation in solid tumours (Weisenthal et
al., 1983; Gazdar et al., 1990).
We are now reporting the final results of this trial.
Methods and materials
Patients
All patients with unresectable NSCLC cared for at the Pettis
Memorial Veterans Hospital were potentially eligible if a
tumour sample could be obtained without major surgery or
incidentally during an otherwise indicated major surgery.
Exclusion criteria were failure to obtain a successful in vitro
assay, a Karnofsky performance score<40, a clinical life
expectance < 1 month, a serum creatinine>2, uncompensat-
*Present address: Oncotech, Inc., 1791 Kaiser Ave, Irvine, CA
92714, USA.
Correspondence: D.W. Wilbur, The Pettis Memorial Veterans Affairs
Medical Center, Loma Linda, CA 92357, USA.
This study was supported by the Department of Veterans Affairs.
Received 6 July 1990; and in revised form 16 August 1991.
ed congestive heart failure or hepatic encephalopathy. Some
patients having a potentially curative resection had an in
vitro study performed on the primary resection specimen. The
initial assay results were then available to arrange treatment
for a later recurrence. The protocol was approved by the
research and human studies committees of the hospital. All
patients gave written consent before treatment.
Tumour specimens
Sterile solid tumour specimens were placed directly in lactat-
ed Ringers solution (without 5% dextrose) and taken to a
laboratory in the same building for mincing and placement in
RPMI-1640 with digesting enzymes. Effusions were collected
in a heparinised container and if greater than 50 ml were
concentrated and reconstituted in 50 ml of autologous fluid.
Specimens were sent by (generally overnight) mail from
Loma Linda, CA to the laboratory in Long Beach, CA where
two of the authors (LMW and PLD) performed the assay.
Assay methodology anddrug selection
Previously published methods were used for the assay (Wei-
senthal et al., 1983; Weisenthal et al., 1986) of the anti-
tumour activity of a panel of ten drugs (nitrogen mustard,
cisplatin, lomustine, carmustine, 5-fluorouracil, doxorubicin,
vinblastine, vincristine, etoposide and mitomycin C). The
DiSC Assay was originally developed to test hematologic
neoplasms which grow poorly in culture. Cells are isolated
from lymph nodes, effusions, or solid tumour biopsies and
cultured in liquid medium in small, polypropylene culture
tubes.
Polypropylene is a slippery material which inhibits the
attachment and growth of normal cells. After 4-6 days in
culture with and without drugs, Fast Green dye is added to
the cultures. This dye penetrates the incompetent membranes
of dead or dying cells and intensely stains the proteins of the
dead or dying cells. Thirty thousand, acetaldehyde-fixed duck
red blood cells (DRBC) are added to each culture as an
internal standard and the entire cell culture is cytocentrifuged
onto a microscope slide. At this point 'living' cells, which
have excluded the Fast Green dye, appear clear and uns-
tained, while 'dead' cells and the DRBC stain bright green.
Slides are then counterstained with either haematoxylin-eosin
or with Wright-Giemsa, which stains the living cells so that
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they can be identified as tumour cells or as normal cells. A
skilled technologist then counts cells to determine the ratio of
'living' tumour cells over DRBC. A ratio of 1:1 in the control
cultures would indicate 30,000 'living' tumour cells, and a
ratio of 0.1:1 in the drug treated cultures would indicate
3,000 'living' tumour cells, or 10% cell survival, relative to
control cultures. Drug concentrations were derived from
training set experiments in which concentrations were sought
which provided a scattered distribution of results when many
different specimens were tested. From the ten drug panel, the
three drugs giving the lowest tumour cell survival in the assay
were chosen for treatment using the scheme in Table I.
Although both carmustine and lomustine were assayed,
lomustine was the only nitrosourea considered for use in
treatment. Thus, values for carmustine were ignored for the
purpose of drug selection but are included in the analysis of
assay/treatment correlations, as described in the Results.
Feasibility analysis
Assays were attempted on 45 patients with previously-
untreated NSCLC. Thirty-five assays were successful and 25
patients ultimately received protocol-assigned treatment.
Assays were attempted on almost all patients (none refused)
who were protocol eligible. These 45 patients came from the
population of 180 consultations provided for all reasons for
non-small cell lung cancer patients during this interval. Of
the 20 patients not treated on protocol, four received chemo-
therapy and none responded. The remaining patients received
'definitive' surgery and/or radiation therapy and/or suppor-
tive care.
Patient evaluation andstatistical methods
All patients treated with even one dose ofchemotherapy were
evaluated for response and survival. The customary defini-
tions were used for partial remission (PR) (as at least a 50%
decrease in measurable tumour) and for complete remission
(CR) (as a disappearance of all known tumour). Bidimen-
sional tumour measurements on chest X-rays and subcu-
taneous tumour nodules were the most common bases for
assessing response. All cases were reviewed by the first
author, with confirmation from his colleagues if the judge-
ment was not obvious. Laboratory tests such as the LDH
were reviewed to confirm responses assessed by tumour
measurements.
Survival curves were calculated by the product limit
method and the BMDP statistical package was used for both
single factor survival comparisons and multivariate propor-
tional hazards modeling of the survival distribution (Dixon et
al., 1985). The Fisher exact test was used for comparisons of
response and survival proportions (Matthews & Farewell,
1988). Differences between sample means were compared by
T test. Tests were either one- or two-tailed, as noted in the
results.
Table I Clinical treatment scheme and in vitro drug concentrations
(g ml') used for testing ('C' =continuous, 4 day drug exposure;
'1 h' = 1 h drug exposure)
In vitro
Drug concentration Clinical scheme 4 week cycles
Cisplatin 1.65°C 60 mg m2 dl (also d8 first 2)
Cyclophosphamidea 1 h 500 mg m-2 dl, d8
Doxorubicin 1.2 1 h 25 mg m-2 dl, d8
Etoposide 41.7°C l00mgm-2 dl, d3, d5
Fluorouracil 20.O°C 600 mg m-2 dl, d8
Lomustine 11.0 1 h 60 mg m-2 dl (q 8 wk after 3)
Mitomycin C 0.3 °C 10 mg m-2 dl (q 8 wk)
Vinblastine 0.55°C 5 mg m-2 dl, d8
Vincristine 0.25°C 1 mg m2 dl, d8
'Nitrogen mustard (3.5 g mll) was the assay surrogate for cyc-
lophosphamide. The three drugs giving the lowest in vitro tumour
survival were combined according to the treatment schedule listed
below.
Results
Treatment results
Some characteristics of the 25 patients at the time of treat-
ment initiation are summarised in Table II. Twenty-three of
the patients had some evidence of tumour beyond the media-
stinum and the other two had bulky mediastinal tumour.
Many of our patients were in poor general condition as
shown by the fact that 12 of 25 had albumin levels less than
3.5. Six patients had a Karnofsky performance score of 60 or
less. The median pretreatment weight loss was 8.5%. Tumour
samples came largely from lymph nodes (mediastinal-4,
supraclavicular-8, peripheral-3) but came also from the
primary (4) and skin/subcutaneous sites (4). The time from
collecting the sample for in vitro study to the initiation of
chemotherapy was 6 to 439 days but was <32 days in 21 of
the 25 patients. In only two cases were results from less than
the full panel of nine drugs used.
Early deaths (2 in < 21 days) or failures to return for
follow up (1) were considered treatment failures. Table III
gives data on response frequency and duration. A 36%
objective PR rate was seen with a median survival of 202
days and a median time to progression of 118 days.
Although it does not prove a therapeutic benefit, it is of
some interest that the responders lived longer than the non-
responders (P = 0.005, one sided). This at least suggests some
biologic differences between these sets of patients. A uni-
variate analysis of clinical data at optimally-selected cut-
points revealed a positive correlation of a number of factors
with survival, including: WBC less than 9,000 (P = 0.02,
two-sided), Karnofsky performance status (KPS) greater than
80 (P = 0.01, one-sided), height/weight squared greater than
22 (P=0.01, one-sided), and weight loss less than 10.1%
(P = 0.02, one-sided). Other independent variables not cor-
related significantly with survival included albumin, LDH,
alkaline phosphatase, haemoglobin, and platelet count.
Although the 15 patients receiving cisplatin had an insigni-
ficantly higher response rate than the patients not receiving
cisplatin, survival for the cisplatin-treated patients was
shorter (median 141 days for cisplatin-treated patients and
219 days for non-cisplatin-treated patients).
Twenty different drug combinations (of a possible 504)
were used, none more than twice. Of a possible 36 pair-wise
Table II Patients characteristics at entry onto treatment protocol
Characteristics Patients
Number entered 25
Age Mean 64 yrs
Range 41 -78 yrs
Median weight loss 8.5%
Prior complete resection 3
Prior radiation therapy 8
Histology Squamous 4
Large cell 7
Adeno 13
LDH elevated 8
Alkaline phosphate elevated 14
Albumin<3.5 12
Performance score (Karnofsky<60) 6
Table III Response related data
Partial responses' Allpatients 9/25 (36%)
Cisplatin 6/15 (40%)
No cisplatin 3/10 (30%)
Median survivat Allpatients 202 Days
Responders 369
Non-responders 125
Median time to Allpatients 118 Days
progressionc Responders 195
Non-responders 46
aP2 cisplatin vs no cisplatin = 0.69; bPI responders vs non-
responders = 0.005; CP1 responders vs non-responders = 0.0005.ASSAY-DIRECTED CHEMOTHERAPY OF NSCLC 29
drug concentrations, 30 were actually used. The small
number of patients limited interpretation, but Table IV does
provide exploratory response and usage data for single drugs
and for pairs appearing three or more times. Lack of res-
ponse for all eight receiving 5FU is perhaps notable in view
oftheoretical considerations that total cell kill assays, such as
the DiSC assay used in this study, may not provide reliable
predictions for 5FU (see Discussion).
No unique toxicities were seen though the usual side effects
of these agents were observed including haematologic depres-
sion, nausea and anorexia. The most bothersome toxicity was
protracted anorexia and malaise in cisplatin treated patients
even ones who had no complaints of nausea with treatment.
This caused delay or interruption of treatment in almost half
the cisplatin treated patients.
Assay/treatment correlations
We also looked for correlations between the level of in vitro
drug resistance and the clinical outcome of response and
survival. For this analysis, we addressed two separate issues.
First, did responding and non-responding patients have
measurable differences in drug resistance in vitro? Second, at
specific assay cut-off points, was in vitro drug resistance
predictive of response or survival?
A series of assay parameters was evaluated for differences
between reponders and non-responders. With the exception
of 5FU, all assay parameters showed a trend for lower assay
cell survival (greater cell kill) in responders than in non-
responders. This was significant for the parameters listed in
Table V, bit not significant in the case of the 'best' single
drug and single drug data for nitrogen mustard, cisplatin,
carmustine, lomustine, vinblastine, vincristine, and mito-
mycin c. A large series ofclinical factors was also reviewed to
Table IV Drugusageandresponse databysingledrugsanddrugpairs
(for drug pairs used three or more times)
Drug(s) Responders/treated
Cisplatin 6/15
Cyclophosphamide 5/15
Doxorubicin 1/2
Etoposide 5/7
5-Fluorouracil 0/8
Lomustine 2/7
Mitomycin c 3/7
Vinblastine 4/10
Vincristine 1/4
Cisplatin/cyclophosphamide 2/7
Cisplatin/etoposide 3/6
Cisplatin/SFU 0/4
Cisplatin/lomustine 1/3
Cisplatin/mitomycin c 2/6
Cisplatin/vinblastine 2/6
Cyclophosphamide/lomustine 2/5
Cyclophosphamide/vinblastine 3/7
Etoposide/vinblastine 2/3
Table V Correlation of clinical response with clinical and assay
parameters
Assay parameters
Parameter Mean (R) Mean (NR) P2
Best three drugs 31 45 <0.05
All ten drugs 56 74 <0.001
Five 'natural products' 53 77 <0.001
Five 'synthetics' 59 72 <0.05
Avg. of CP, VBL, VCR, DOX, 52 78 <0.02
VP16
Avg. of VBL, VCR, DOX, VP16 53 80 <0.025
Avg. of DOX, VP16 52 85 <0.005
Doxorubicin (DOX) 60 83 <0.05
Etoposide (VP16) 44 87 <0.01
White blood cell count 7.9 14 <0.05
Units: Assay - percent cell survival; White blood cell count -
WBC mm-3.
see if there was a correlation between these factors and
patient response. No significant correlation was found in this
small patient group for age, educational level, height divided
by weight squared, Karnofsky Performance Status, prior
weight loss, number of tumour sites, haemoglobin, platelet
count, blood urea nitrogen, albumin, total protein, choles-
terol, alkaline phosphatasae, SGOT, SGPT, LDH, CEA,
creatinine, uric acid or RBC volume. As shown in Table V,
there was a significant correlation for white blood cell count,
with non-responders showing a higher WBC. However, the
correlations with clinical response were stronger in the case
of the DiSC assay than in the case of the clinical factors
(data above and in Table V).
Table VI shows correlations between treatment results and
assay results for individual patients. Assay results were used
to make three different indices of sensitivity. These consisted
of the values for the most effective drug, the average of the
values for the three best drugs and the average for all ten
drugs in the panel. Patients were separated into two popula-
tions using these three indices with cut points at 21%, 31%
and 61% respectively for in vitro cell survival. Response rates
were better for patients with tumour that had lower cell
survival in vitro. Responding patients who were also assay
'sensitive' had the most favourable survival (median 469
days, n = 6).
Comparisons between different single drugs and different
three drug groups in patients treated with a variety of three
drug combinations suffer from theoretical weaknesses, as
considered in the Discussion. More significant correlations
were obtained by comparing the test results from the same
drug or same groups of drugs in all patients, also shown in
Table VI. Thus, results with etoposide alone or with the
average results of drug groups correlated significantly with
response.
Figure 1 shows that differences in response proportions
persisted at different assay cut-off points between in vitro
'sensitive; and 'resistant'. At each cut-off, it was possible to
separate patients into groups with higher and lower response
probabilities. Similar findings were obtained when results
were based on the average results from drug groups (data not
shown). When assay results were cut at the median assay
values, the results with etoposide alone (Figure 2) and with
the average of the drug groups (data not shown) correlated
significantly with median duration of survival according to
generalised Wilcoxon test (P = 0.04, one-sided), despite the
presence of a remarkable patient, 'resistant' in the assay, who
had progressive disease during the first cycles of chemo-
therapy, but who, none-the-less, survived 868 days.
Discussion
Treatment outcome
In this trial, outcome as measured by response rate and
survival was within the ranges reported in the literature,
Table VI Correlations between assay and response NSC lung
cancer
Criterion of Responders/Total
Drug(s) correlated resistance 'Sens' assay 'Res' assay Pla
'Best' one >21% 6/12 3/13 0.16
'Best' three >31% 6/10 3/15 0.053
All ten >61% 6/10 3/15 0.053
Etoposide (E) >61% 7/12 2/13 0.033
Etoposide (E) > 71% 8/14 1/11 0.017
Etoposide (E) >81% 8/15 1/10 0.034
CP,Vbl,Vcr,Dox,E > 61% 6/9 3/14 0.041
CP,Vbl,Vcr,Dox,E > 71% 8/12 1/11 0.0069
CP,Vbl,Vcr,Dox,E > 81% 9/17 0/6 0.030
Vbl,Vcr,Dox,E > 61% 7/11 2/13 0.021
Vbl,Vcr,Dox,E >71% 9/15 0/9 0.0038
Vbl,Vcr,Diox,E >81% 9/16 0/8 0.0087
aPI: fisher exact test (one-sided) for response rate for patients with
'sensitive' assay vs response rate for patients with 'resistant' assay.30 D.W. WILBUR et al.
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Figure 1 Correlations between in vitro resistance to etoposide
and clinical response to chemotherapy with a variety of assay-
directed three drug combinations. Comparisons are made at a
variety of assay cut-off points. Open ovals represent the response
rate observed in patients with assay results falling below the
cut-off point (i.e. assay 'sensitive') and closed ovals represent the
response rate for patients with assay results falling above the
cut-off point (i.e. assay 'resistant'). The dotted line represents the
overall response rate for all 25 patients (36%). Significance tests
are Fisher exact tests (one-sided) testing proportions of patients
responding or not responding for assay results falling below or
above each cut-off point. At all cut-off points, the assay divided
patients into groups with higher or lower than expected prob-
abilities of responding to combination chemotherapy. O<Cut-
off; *>Cut off. *P<0.05.
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Figure 2 Survival from the data of first treatment of all 25
patients receiving assay-directed therapy. Two curves are depict-
ed, each representing the survival of patients with assay results to
etoposide falling below or above the median result for all etopo-
side assays. Assay results of etoposide falling below the median
are labelled 'Sensitive' (for the purposes of this comparison),
while assay results falling above the median are labelled 'resis-
tant'. Assay 'resistant' patients had an inferior survival (P = 0.04,
one-sided Wilcoxon test). VPl6 'Sensitive' (Assay below
median); --- VP16 'Resistant' (Assay above median).
although our patient population contained some patients (PS
60 or less and/or brain metastases) who would not be eligible
for most cooperative group trials. Though one recent pros-
pective, randomised trial was reported a survival benefit for
patients treated with combination chemotherapy (Rapp et al.,
1988), other recent trials of similar treatments have not
confirmed this finding (Woods et al., 1990; Luedke et al.,
1987; Ganz et al., 1989). We feel that continued innovative
trials are much needed. However, in order to demonstrate a
25% improvement in median survival in a randomised trial
through assay-directed drug selection, 600 patients would be
required (one-sided test, power of 0.8, allowing also for a
20% assay inevaluability rate). Unfortunately, in a recent
Eastern Cooperative Group trial to evaluate the DiSC assay
in. NSCLC (EST B-585), five patients were accrued in 12
months (LMW, unpublished experience).
Technical and theoretical considerations regarding assay
methodology
The DiSC Assay, studied here, is quite different from the
'clonogenic' assays more extensively studied by previous
investigators (von Hoff et al., 1981; Scheithauer et al., 1988;
Salmon, 1987; Hanauske et al., 1987; von Hoff, 1987; Hana-
uske & von Hoff, 1986; Link et al., 1986; Sondak et al.,
1985). The endpoint of this assay is cytolysis (direct cell
killing which results in loss ofmembrane integrity), as oppos-
ed to inhibition of cell proliferation, which is measured in
'clonogenic' assays. Furthermore, cytolysis in the DiSC
Assay is measured in the entire tumour cell population,
which consists of largely non-proliferating cells.
The theories behind this assay have been previously con-
sidered (Weisenthal et al., 1983; Weisenthal et al., 1984;
Weisenthal & Lippman, 1985; Weisenthal et al., 1986; Weis-
enthal, 1987; Weisenthal et al., 1988; Weisenthal, 1991).
Briefly, the assay is theoretically valid in situations where the
clinical mechanisms of resistance are similar to the in vitro
mechanisms of resistance, even when the in vitro endpoint is
not the same as the most important clinical effect. For exam-
ple, etoposide may (hypothetically) prevent cell division
(putatively, the most important clinical effect) if it produces
one unrepaired DNA strand lesion. In vitro, it may produce
cytolysis in a non-dividing tumour cell only by producing
multiple unrepaired DNA strand lesions, resulting in impair-
ed RNA synthesis or by producing ATP depletion as a
by-product of excessive synthesis of poly-ADP-ribose (Car-
son et al., 1986; Berger, 1985). These cellular lesions may be
achieved only through the use of relatively high in vitro drug
concentrations. Yet the mechanisms protecting the reproduc-
tive integrity of the cell at low (clinical) drug concentrations
(e.g. diminished drug transport, enhanced drug export, alter-
ed topoisomerase activity, and increased repair efficiency)
may be similar and proportional to the mechanisms protect-
ing the cytologic integrity at high (in vitro) drug concentra-
tions. Thus, if one calibrates the assay at a certain drug
concentration and assay duration, then testing a variety of
tumours under the same conditions can plausibly discrimin-
ate between cell populations with differing in vitro levels of
resistance which reflect differing clinical levels of resistance.
On the other hand, with other drugs in vitro resistance may
not parallel clinical resistance. For example, if the most
important clinical effect of 5FU is the inhibition of cell
division through the inhibition of thymidylate synthetase,
then measuring cytolysis in non-dividing cells in vitro (e.g.
mediated through incorporation of 5FU into 'fraudulent'
RNA) may not give assay results correlating with clinical
drug resistance. These theoretical considerations also apply
to other assay systems measuring cell damage in the total
(largely non-dividing) tumour cell population (e.g. (Rotman
et al., 1988; Campling et al., 1988)). In our present study, it
was striking that none of the eight patients assigned to
receive chemotherapy which included 5FU responded. Cer-
tainly, we would not, in future trials, include 5FU as a drug
to be selected by the results of any in vitro assay which
measures cell damage in the total tumour cell population.
At the concentrations tested in the assay, nitrogen mustard
was, on the average, the most active agent and was signi-
ficantly more active than were several other drugs, such as
etoposide. This probably does not reflect the clinical situation
and most likely resulted from testing a disproportionately
high concentration of nitrogen mustard in vitro, relative to
the concentrations of the other agents tested.
The above considerations point out the difficulty of com-
paring the results of (for example) 5FU treatment and drug
resistance assay in one patient with etoposide treatment and
assay in another patient. Firstly, the assay may be valid for
etoposide and not valid for 5FU and, therefore, a 20% cell
survival assay result for etoposide in patient A would not
likely be comparable to a 20% cell survival assay result for
5FU in patient B. Secondly, the assay could be individually
valid for both drugs, but the drug concentrations tested
might not be calibrated precisely enough to allow direct
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comparison between percent cell survivals in vitro (e.g. 50%
cell survival in vitro might indicate drug sensitivity at the
concentration tested for etoposide, while 20% cell survival in
vitro might be required to indicate drug sensitivity at the
concentration tested for nitrogen mustard). However, com-
parisons of the same drug at the same concentration in
different patients may be more valid (e.g. 50% cell survival to
etoposde in patient A might indicate greater drug sensitivity
to etoposide than 100% cell survival to etoposide in patient
B). These latter considerations point out a weakness in the
present study, where drugs were selected on the basis of the
lowest absolute cell survival, rather than on the basis of a
calibrated, 'normalised' value (e.g. deviation from the median
result of all assays with a given drug, see below), which
could, on the basis of the data obtained in the present study,
now be calculated for subsequent assays.
Predictive accuracy ofassay
All cell culture assays are, for biological and statistical
reasons, much better at detecting drug resistance than drug
sensitivity (Weisenthal, 1991). For this reason, it is perhaps
unfair to assess the predictive accuracy of a particular assay
system in a study where the drugs found to be most assay-
resistant (the most accurate predictions) are specifically ex-
cluded from use in patient treatment. Despite the fact that
the design of the present study was, therefore, not optimum
for determining the predictive accuracy of the DiSC Assay
system in NSCLC (which would require all patients to be
treated in a uniform fashion, irrespective of assay results),
we were none-the-less able to demonstrate significant assoc-
iations between in vitro drug resistance and response.
Specimens from responding patients were, on the whole,
significantly more sensitive to individual drugs, groups of
drugs, and the drugs used in treatment than were specimens
from non-responding patients. In vitro drug resistance differ-
ences between responding and non-responding patients were
of greater significance than were differences between other
laboratory and clinical measurements.
We found that the clearest correlations between clinical
and in vitro drug resistance were obtained when the same
drug(s) was(were) compared for all patients, regardless of the
treatment they received. This finding is consistent with the
theoretical considerations discussed earlier. Correlations were
best in the case of etoposide (Tables V and VI, and Figures 1
and 2) and correlations were further improved by taking an
average of several drugs, such as the average results for
etoposide, doxorubicin, cisplatin, and vincristine. Some years
ago, previous authors reported (using a different assay
system) that the results of doxorubicin in vitro were highly
predictive of the general clinical effectiveness of multiple
different drugs (Groups for sensitivity testing of tumours
(KSST), 1981). This finding seemed somewhat improbable at
the time, but recent work on the phenomenon of multidrug
resistance provides a logical explanation to support the credi-
bility of these earlier findings. Our own results are consistent
with these observations. Our findings showed clear and signi-
ficant associations between the general in vitro drug resis-
tance to groups of drugs and the clinical response to multiple
forms of three drug combination chemotherapy. We specu-
late that these associations might have been even more signi-
ficant had patients all received uniform therapy with, for
example, cisplatin-etoposide, but it will require further study
to confirm or refute this speculation.
In other studies of drug resistance assays (Weisenthal,
1991; Weisenthal & Kern, 1991; Kern & Weisenthal, 1990;
Weisenthal et al., 1990; Bosanquet, 1991), results were cut at
the median and at one standard deviation greater than (more
resistant than) the median, identifying cohorts of patients
with above-expected, below expected, and no chance of
response. Results falling one or more standard deviations
more resistant than the median were said to signify extreme
drug resistance (EDR). In 50 assays successfully testing all 10
drugs performed on non-small cell lung cancer specimens
(comprising assays for the present study and additional
assays performed on specimens from other institutions), the
median result for the average of all ten tested drugs was 59%
cell survival and one standard deviation was 26%. Cutting
assay results at the median and at one standard deviation
greater than the median resulted in patient cohorts with
response rates of 6/11 (55%), 3/9 (33%), and 0/5 (0%) for
results less than the median, greater than the median to one
standard deviation greater than the median, and greater than
one standard deviation greater than the median, respectively.
Although the numbers are small, these results offer further
support for the concept of EDR as an objective phenomenon
that can be identified as a cell culture assay result falling one
standard deviation more resistant than the median of all
assay results (ibid). It may be quite valuable to identify
subsets of patients with very low response probabilities, to
avoid the toxicity and expense of ineffective therapies, and, in
turn, to identify patients who are better candidates for inves-
tigational trials than for 'standard' therapies with a very low
likelihood of success. Another potentially useful application
of such assays in NSCLC may be the selection of patients
most likely to benefit from adjuvant chemotherapy to be
administered along with surgery or radiation therapy (those
patients with tumours not expressing EDR).
Recently, Gazdar and colleagues reported that a highly
drug-resistant subset of small cell lung cancer patients was
identified by the DiSC assay when this test was applied to
early passage cell lines established from individual patients.
Additionally, assay results were found to correlate both with
response and with patient survival (Gazdar et al., 1990). The
DiSC assay has also been shown to correlate with response
(Lathan et al., 1990; Tidefelt et al., 1989; Beksac et al., 1988;
Kirkpatrick et al., 1990; Weisenthal et al., 1986; Bosanquet,
1991) and survival (Tidefelt et al., 1989; Bosanquet, 1991) in
haematologic neoplasms. While the DiSC assay has previous-
ly been studied mainly in the case of haematologic neo-
plasms, other types of assay systems have been much more
extensively studied in solid tumours (von Hoff et al., 1981;
Scheithauer et al., 1988; Salmon, 1987; Hanauske et al., 1987;
von Hoff, 1987; Hanauske & von Hoff, 1986; Link et al.,
1986; Sondak et al., 1985). A recent analysis of a soft agar
cell proliferation assay revealed that large numbers of drug-
resistant tumours could be identified in solid tumour patients
with 99.2% specificity for the extreme drug resistance end-
point (Kern & Weisenthal, 1990).
Conclusions
In conclusion, the results of the present study strongly sug-
gest that the DiSC assay is clinically relevant for etoposide
and probably for other drugs but possibly not for 5FU.
These experimental observations are also consistent with
some of the theoretical considerations discussed above. The
data further suggest that assay results may be used to classify
patients prior to treatment into distinct cohorts, having
above average and below average probabilities of responding
to chemotherapy (Figure 1, Table V). These preliminary data
also suggest that the DiSC assay may be used to identify
tumours with extreme drug resistance (EDR), using assay
criteria similar to those previously proposed in other publica-
tions (Kern & Weisenthal, 1990; Weisenthal et al., 1990;
Bosanquet, 1991; Weisenthal, 1991; Weisenthal & Kern,
1991). Although our series is small, results are sufficiently
encouraging to support the initiation of further trials, includ-
ing comparisons with other cell culture drug resistance assays
and with other (non-cell culture) tests for drug resistance,
such as P-glycoprotein (Merkel et al., 1988; Lai et al., 1989)
and neuroendocrine markers (Graziano et al., 1989).32 D.W. WILBUR et al.
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